Abstracts tagged "Biomarkers"

Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 1588 • 2016 ACR/ARHP Annual Meeting
Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
Sudha Visvanathan¹, Meera Ramanujam¹, Corinna Schoelch², Patrick Baum², Richard Vinisko¹, Ralf Thiedmann², Ulf Müller-Ladner³, Stefan Daniluk⁴, Rafal Ptaszyński⁵, Steven Padula⁶, Jay S. Fine¹ and Jürgen Steffgen², ¹Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ²Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ³Giessen University, Kerckhoff-Klinik, Bad-Nauheim, Germany, ⁴ClinicMed Badurski and Partners, Bialystok, Poland, ⁵Rheumatica, Warsaw, Poland, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Background/Purpose: Costimulation through the CD40–CD40L axis is implicated in the pathogenesis of RA including T cell-mediated responses, B cell-driven autoantibodies, adhesion molecule expression, synovial hyperplasia…
Abstract Number: 2125 • 2016 ACR/ARHP Annual Meeting
Aggrecan Degradation Is Not Just Aggrecan Degradation:a Study of the Neo-Epitopes Tege and Args Released from Cartilage upon Aggrecanase Activity
Anne Sofie Siebuhr¹, Yi He², Yunyun Lou², Sabine Hoielt³, Morten Asser Karsdal¹ and Anne C. Bay-Jensen¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Rheumatology, Nordic Bioscience, Biomarkers and Research, 2730, Denmark
Background/Purpose: Cartilage degradation is a hallmark of arthritic disease. The main constituents of cartilage is aggrecan and type II collagen. Previous studies have shown that…
Abstract Number: 2585 • 2016 ACR/ARHP Annual Meeting
Serum MMP-3 and OPG As Predictors of Response to Traditional Dmards in a Treatment NaïVe Early Rheumatoid Arthritis Cohort
Pieter Meyer¹, mahmood Mtm ally¹, Bridget Hodkinson², Eustasius Musenge³, piet becker¹, Mohammed Tikly⁴ and Ronald Anderson⁵, ¹university of pretoria, pretoria, South Africa, ²university of cape town, cape town, South Africa, ³University of Witwatersrand, Johannesburg, South Africa, ⁴university of witwatersrand, Johannesburg, South Africa, ⁵University of Pretoria, Pretoria, South Africa
Background/Purpose: Bone and cartilaginous metabolites such as matrix metalloproteinase 3 (MMP-3), cartilage oligomeric matrix protein (COMP),receptor activator for nuclear factor κ B ligand (RANKL) and…
Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Emily Bowers¹, M. Kristen Demoruelle², Michael Weisman³, Jill M. Norris⁴, William H. Robinson⁵, V. Michael Holers² and Kevin D. Deane², ¹Medicine, University of Colorado Denver, Aurora, CO, ²Rheumatology Division, University of Colorado Denver, Aurora, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Stanford University School of Medicine, Stanford, CA
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…
Abstract Number: 279 • 2016 ACR/ARHP Annual Meeting
Increased Heat Shock Protein 90 in Muscle Tissue and Plasma in Idiopathic Inflammatory Myopathies Correlates with Disease Activity and Skeletal Muscle Involvement
Hana Storkanova¹, Olga Krystufkova¹, Martin Klein², Herman F Mann¹, Lucia Vernerova¹, Maja Spiritovic^1,3, Josef Zámecník⁴, Karel Pavelka², Ladislav Senolt¹, Jiří Vencovský¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic
Background/Purpose: Heat shock proteins (Hsps) are chaperones playing important roles in skeletal muscle physiology, adaptation to exercise or stress, and activation of inflammatory cells. The…
Abstract Number: 869 • 2016 ACR/ARHP Annual Meeting
Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Abraham Rutgers¹, Suzanne Arends¹, Annemieke M.H. Boots¹ and Elisabeth Brouwer³, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) is the most frequent inflammatory disorder in persons older than 50 years of age. Biomarkers like ESR and CRP may be…
Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Boel Brynedal¹, Helga Westerlind², Lasse Folkersen^3,4, Leonid Padyukov⁵, Nancy Vivar⁵, Anca I Catrina⁶, Lars Klareskog⁵ and Louise Berg⁵, ¹Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ²Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…
Abstract Number: 2135 • 2016 ACR/ARHP Annual Meeting
Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Anne C. Bay-Jensen¹, Steven B. Abramson², Jonathan Samuels³, Inger Byrjalsen⁴, Svetlana Krasnokutsky Samuels⁵, Tina Manon-Jensen⁶, Morten Asser Karsdal¹ and Mukundan Attur⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ³Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, ⁴Nordic Bioscience, Clinical Development, Herlev, Denmark, ⁵Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁷Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease characterized by pain and tissue destruction, in some cases concomitant with inflammation. The link between pain and tissue destruction…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Yahui Grace Chiu¹, Edward Schwarz², Richard Bell³, Dongge Li⁴, Nelson Huertas⁴, Cristy Bell⁵, Sharon Moorehead⁵, Debbie Campbell⁵, Changyong Feng⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Statistics, University of Rochester, Rochester, NY, ⁷Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…
Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen², Jeppe Andersen³, Christian S. Thudium⁴, Bente J. Riis², Claus Christiansen², Hans Guehring⁵, Martin Michaelis⁵, Christoph Ladel⁵ and Morten Asser Karsdal⁶, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Merck KGaA, Darmstadt, Germany, ⁶Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…
Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Seunghee Hong¹, Romain Banchereau¹, Marta M. Guerra², Jane E. Salmon^3,4 and Virginia Pascual¹, ¹Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ²Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…
Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Natasja Stæhr Gudman¹, Pernille Juhl², Christian S. Thudium³, Anne Sofie Siebuhr⁴, Inger Byrjalsen⁵, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…
Abstract Number: 2136 • 2016 ACR/ARHP Annual Meeting
CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model
Nisha Sambamurthy^1,2, Vu Nguyen^1,2, Ryan Smalley^2,3, George R. Dodge^3,4 and Carla R. Scanzello^1,2,3, ¹Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Translational Musculoskeletal Research Center, CMC Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Orthopedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Research, CMC Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: CD14, though expressed by multiple cell types, is highly expressed by monocytes and macrophages. It forms a complex with Toll-like receptors (TLRs), particularly TLR-2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].